RayKnowChina Research Map
Shortlist0

RecruitingStomach cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

A Random, Non-controlled, Open Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxel ± Adebrelimab in Treating Advanced Second-line Gastric Cancer

An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by First Affiliated Hospital of Zhengzhou University; 1 other hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 2

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
  2. Study siteFirst Affiliated Hospital of Henan University of Science and Technology河南科技大学第一附属医院LuoyangHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07770113, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 80 years; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma, locally advanced and unresectable, with local recurrence or distant metastasis;

    Inclusion criterion 4

  3. Gastric adenocarcinoma or gastroesophageal junction adenocarcinoma that has failed first-line systemic therapy: (1) Patients with postoperative recurrence or metastasis who progress during concurrent chemoradiotherapy also qualify; (2) For neoadjuvant/adjuvant therapy, if the patient progresses during treatment or within 6 months after treatment, it is also considered first-line systemic therapy failure; (3) If first-line therapy included immunotherapy, the PFS of a regimen containing immune checkpoint inhibitors must be at least 5 months;

    Inclusion criterion 6

  4. ECOG score 0-1;

    Inclusion criterion 3

  5. Patient has at least one measurable lesion (according to RECIST 1.1 criteria);

    Inclusion criterion 7

  6. History of immunodeficiency, including positive HIV testing, or other acquired or pre-acquired conditions Congenital immunodeficiency diseases, or history of organ transplantation and allogeneic bone marrow transplantation;

    Exclusion criterion 5

    Before using the study drug for the first time, diagnosed with any other malignant tumor, except for those with low risk of metastasis and death (5-year survival rate >90%), such as fully treated basal cell or squamous cell skin cancer or cervical carcinoma in situ;

    Exclusion criterion 8

  7. Women of childbearing potential must agree to use effective contraception during the study and for 6 months after the study; must have a negative serum or urine pregnancy test within 7 days before enrollment, and must not be breastfeeding; men must agree to use contraception during the study and for 6 months after the study.

    Inclusion criterion 9

    Pregnant or breastfeeding women; subjects of reproductive potential who are unwilling or unable to use effective contraception;

    Exclusion criterion 9

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07770113, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Fully understand this study and voluntarily sign the informed consent form, with good compliance and cooperation during follow-up;
  • Age ≥18 years and ≤80 years;
  • ECOG score 0-1;
  • Histologically or cytologically confirmed gastric adenocarcinoma or gastroesophageal junction adenocarcinoma, locally advanced and unresectable, with local recurrence or distant metastasis;
  • Her2 negative;
  • Gastric adenocarcinoma or gastroesophageal junction adenocarcinoma that has failed first-line systemic therapy: (1) Patients with postoperative recurrence or metastasis who progress during concurrent chemoradiotherapy also qualify; (2) For neoadjuvant/adjuvant therapy, if the patient progresses during treatment or within 6 months after treatment, it is also considered first-line systemic therapy failure; (3) If first-line therapy included immunotherapy, the PFS of a regimen containing immune checkpoint inhibitors must be at least 5 months;
  • Patient has at least one measurable lesion (according to RECIST 1.1 criteria);
  • Major organ function is normal, i.e., meeting the following criteria:(1) Blood routine test standards must meet the following (no blood transfusion or blood products within 14 days, no use of G-CSF or other hematopoietic stimulating factors for correction):

A. Hemoglobin (Hb) ≥ 90 g/L; B. Absolute neutrophil count (ANC) ≥ 1.5 × 10\^9/L; C. Platelet count (PLT) ≥ 80 × 10\^9/L;

(2) Biochemical test standards must meet the following: A. Total bilirubin (TBIL) < 1.5 times the upper limit of normal (ULN); B. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 ULN, and < 5 ULN for liver metastasis patients; C. Serum creatinine (Cr) ≤ 1.5 ULN or estimated creatinine clearance > 60 ml/min (Cockcroft-Gault formula); D. Urinalysis shows protein (UPRO) < 2 or 24-hour urine protein < 1 g;

(3) Doppler ultrasound assessment: left ventricular ejection fraction (LVEF) ≥ lower limit of normal (50%);

(4) Coagulation function: international normalized ratio (INR) ≤1.5 × ULN and activated partial thromboplastin time ≤1.5 × ULN;

(5) Lung function: forced expiratory volume in 1 second (FEV1) ≥1.2 L, FEV1% ≥50%, carbon monoxide diffusing capacity (DLCO) ≥50%;

(6) Echocardiography: left ventricular ejection fraction (LVEF) ≥50%;

(7) Electrocardiogram: QT interval corrected by Fridericia method (QTcF) <470 ms for females, <450 ms for males;

(8) Others: lipase ≤1.5 × ULN (patients with lipase >1.5 × ULN can be included if there is no clinical or imaging evidence of pancreatitis); amylase ≤1.5 × ULN (patients with amylase >1.5 × ULN can be included if there is no clinical or imaging evidence of pancreatitis); alkaline phosphatase (ALP) ≤2.5 ULN.

  • Women of childbearing potential must agree to use effective contraception during the study and for 6 months after the study; must have a negative serum or urine pregnancy test within 7 days before enrollment, and must not be breastfeeding; men must agree to use contraception during the study and for 6 months after the study.

Exclusion Criteria:

  • Those allergic to therapeutic drugs or those who have received first-line investigational drug treatment;
  • Patients who have received first-line VEGFR inhibitor therapy, such as sorafenib, sunitinib, apatinib, etc.; Patients who have received first-line paclitaxel drugs.
  • (1) Have received any investigational drug within 4 weeks prior to first use; (2) Subjects who require systemic corticosteroids (> 10 mg prednisone equivalent daily) or other immunosuppressants within 2 weeks prior to first use of the study drug, excluding cases of corticosteroid use targeting local esophageal inflammation and preventing allergies, nausea, and vomiting. (3) Other special circumstances require communication with the sponsor. In the absence of active autoimmune disease, inhaled or topical corticosteroids and adrenal corticosteroid replacement doses > 10 mg/day of prednisone are permitted; (4) Those who have received anti-tumor vaccines or received live vaccines within 4 weeks prior to the first administration of the study drug;
  • Having any active autoimmune disease or a history of autoimmune diseases (such as interstitial lung).

inflammation, uveitis, enteritis, hepatitis, pituititis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism); Excluding vitiligo or patients with recovered childhood asthma/allergies who do not require any intervention in adulthood; Patients with autoimmune-mediated hypothyroidism treated with stable doses of thyroid replacement hormone and type I diabetes patients on stable doses of insulin may be included;

  • History of immunodeficiency, including positive HIV testing, or other acquired or pre-acquired conditions Congenital immunodeficiency diseases, or history of organ transplantation and allogeneic bone marrow transplantation;
  • Uncontrolled cardiac clinical symptoms or diseases, such as (1) NYHA II or above Heart failure (2) Unstable angina pectoris (3) Myocardial infarction within 1 year (4) Subjects with clinically significant supraventricular or ventricular arrhythmias requiring clinical intervention;
  • Severe infection within 4 weeks prior to first use of the study drug (CTC AE> level 2), Such as severe pneumonia, bacteremia, or complications such as infections requiring hospitalization; Baseline chest imaging indicates active lung inflammation, symptoms and signs of infection within 2 weeks prior to first use of the study drug, requiring oral or intravenous antibiotic treatment, except for prophylactic antibiotic use; History of interstitial lung disease, non-infectious pneumonia, pulmonary fibrosis, or other uncontrolled acute lung diseases; Patients with active pulmonary tuberculosis infection found through medical history or CT scan, or those with a history of active pulmonary tuberculosis infection within the past year prior to enrollment, or those with a history of active tuberculosis infection more than 1 year ago without formal treatment; Subjects with active hepatitis B (HBV DNA ≥ 2000 IU/mL or 104 copies/mL), hepatitis C (hepatitis C antibody positive, HCV-RNA above the detection lower limit of the assay);
  • Before using the study drug for the first time, diagnosed with any other malignant tumor, except for those with low risk of metastasis and death (5-year survival rate >90%), such as fully treated basal cell or squamous cell skin cancer or cervical carcinoma in situ;
  • Pregnant or breastfeeding women; subjects of reproductive potential who are unwilling or unable to use effective contraception;
  • Patients deemed unsuitable for enrollment according to the investigator's judgment.

Quoted from ClinicalTrials.gov, NCT07770113, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07770113, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07770113